Ixekizumab + Tirzepatide boosts psoriatic arthritis outcomes more tha… | HappeningNow.news
Published Date: April 19, 2026

Ixekizumab + Tirzepatide boosts psoriatic arthritis outcomes more than Ixekizumab monotherapy

Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to…

Health Medicalxpress

AI Summary Powered by HappeningNow

Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

AI summaries can be wrong sometimes—always verify important details using the source link below.

Read full article at medicalxpress.com
Category Health
Outlet Medicalxpress
Source medicalxpress.com
Return Home